Therefore targeting ERK in pancreatic cancer patients will not specifically block signals from Trop2, but would rather block a number of signals which result in the activation of ERK such as those induced by KRAS mutations. This evidence concerns the gene MAPK1 and familial pancreatic carcinoma.